3D structure of PI3Kdelta: An important drug target for a wide range of diseases

NewsGuard 100/100 Score

Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.

The paper provides the first glimpse at the three-dimensional structure of PI3Kdelta (p110delta), an important drug target implicated in a wide range of diseases, including cancer, asthma and rheumatoid arthritis.  There has been intense interest in the design of selective inhibitors against the family of PI3K drug targets, and this paper reports the atomic structure of the PI3Kdelta enzyme co-crystallized with both broad spectrum and isoform-selective inhibitors.

The pioneering work was the result of a collaboration led by Roger Williams, Ph.D., Professor in the Laboratory of Molecular Biology at the Medical Research Council in Cambridge, U.K., and it included scientists from the University of California, San Francisco, Intellikine in La Jolla, California, and Merck-Serono Research Center in Geneva, Switzerland.

"This work is significant in that it explains for the first time the structure-based design of highly-selective inhibitors of PI3Kdelta," said Kevan Shokat, Ph.D., Professor of Chemistry and Howard Hughes Medical Institute Investigator at the University of California, San Francisco.  "Nine structurally-distinct inhibitors are reported and, as such, this paper represents the cutting-edge of isoform-selective inhibitor design in the PI3K drug target family."  Professor Shokat heads the UCSF team that contributed to the collaboration and is a co-founder of Intellikine.

"We believe that the discovery of isoform-selective inhibitors is critical if chronic treatment with kinase inhibitors is to become reality," added Christian Rommel, Ph.D., Chief Scientific Officer of Intellikine.  "Over the past several years, we have exploited the insights from these co-crystal structures to design multiple series of isoform-selective inhibitors, and this work was instrumental to our designing INK1197, an exquisitely selective inhibitor which we are advancing as a therapy for inflammatory and respiratory disease."


Intellikine, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds